22-04-2014: Penn Pharma, a leading global provider of integrated drug development, clinical trial supply and manufacturing services to the international healthcare industry, today announced the completion of potent compound safety training and certification for its staff through Affygility Solutions.
Penn Pharma officially opened a new purpose-built contained manufacturing facility in September 2013 and the training and subsequent certification of its staff was a critical factor milestone to achieve.
Penn Pharma selected Affygility Solutions to complete the training certification based on the specific expertise offered by Affygility Solutions in potent compound safety. Affygility Solutions also offered a unique and flexible webinar format allowing Penn Pharma staff to attend from multiple global locations.
The training was extremely comprehensive and included; Introduction to Potent Compound Safety, Toxicology, Industrial Hygiene, Banding and Control Strategies and the Manufacturing of Highly Potent Compounds including both understanding and controlling the risks.
This comprehensive programme along with the flexibility of training made Affygility Solutions the perfect partner for Penn Pharma.
Penn Pharma Chief Operating Officer, Mark Dean Netscher, commented: “We are extremely pleased to have our staff complete the potent compound safety training certification process.
“This is an important component of our continued commitment to employee safety and Operational Excellence in Penn as we continue to demonstrate leadership of the handling, development and manufacturing of potent products in our contained manufacturing facility.”